MabVax Therapeutics Holdings Inc
MabVax Therapeutics — Investor Presentation (September 2017)
33 slides from MabVax Therapeutics's investor presentation, Sep 12, 2017
Slide 1: MabVax Therapeutics Company Presentation September 2017
\y/ MabVax therapeutics Company Presentation September 2017 NASDAQ: MBVX ‘wirenabvatlae
Slide 2: Forward Looking Statements
Forward Looking Statements This presentation contains forward-looking statements and projections. The company makes no express or implied representation or warranty as to the completeness of this information or, inthe case of the projections, as to their attainabilty or the accuracy and completeness
Slide 3: Safety and Targeting Specificity demonstrated
M nasdaq Safety and Targeting Specificity demonstrated two Phase @-O- Hes patients Robust research portfolio includes advanced Tn program for ovarian and triple negative breast cancer 3 ACTIVE PHASE 1 NASDAQ listed (MBVX) TRIALS Value Proposition: Fully human antibody discovery and development platf
Slide 4: MabVax Terminology and Nomenclature
M MabVax Terminology and Nomenclature * HuMab-5B1: Parental antibody discovered from a cancer patient vaccinated with a sialyl-lewis* vaccine + MVT-5873: HuMab-581 antibody formulated for parenteral administration and evaluated in Phase 1 clinical trials asa single agent and in combination with gemc
Slide 5: Company Background
i, COMPANY BACKGROUND
Slide 6: Company Overview
Fully-Human Antibody Discovery Platform ‘linical Stage Research and Development Company Clinical Pathway Established for Lead Asset Key Collaborations Company Overview MabVax is an antibody discovery and development company with products that were discovered from the immune response of cancer patien
Slide 7: Clinical and Scientific Progress on Unique Therapeutic and Diagnostic Products
Clinical and Scientific Progress on Unique Therapeutic and Diagnostic Products Based on HuMab-5B1 MVT-S873 clinical trial demonstrates early safety (efficacy signal MVT-2163 clinical trial demonstrates early safety/ specificity MVT-1075 clinical trial underway Expansion to other cancers expressing s
Slide 8: Management Team
4. David Hansen President, CEO and Chairman DUTA 9 PScreringPough FB wis hers Squib Gregory P. Hanson, CMA, MBA Chief Financial Officer Philip O. Livingston, M.D. Chief Scientific officer Poul, Mai Ph . Cintenechoniberioonent AH Em &Y™ © Paul F, Resnick, M.D. a. c — Vrandchet Busnes otter ventas tel
Slide 9: Board of Directors
Board of Directors Mi J. David Hansen Jeffrey F. Eisenberg President, CEO and Chairman of MabVax Former CEO Noven Pharmaceuticals, Former Acting Gen Counsel IVAX Paul V. Maier Former CFO Sequenom Inc., Former St. VP & CFO Ligand Pharmaceuticals Philip 0. Livingston, M.O. Chief Scientific Officer of
Slide 10: Discovery Platform
i, DISCOVERY PLATFORM
Slide 11: Human Antibody (HuMab) Discovery Platform
Human Antibody (HuMab) Discovery Platform Proprietary Approach to the Discovery and Development of Novel Fully Human Antibody Therapy and Diagnostic Agents Focused Discovery Screening Optimized Therapy Fully human antibody ‘minimizes immunogenicity. Binding sequence reflects the patient's immune sys
Slide 12: HuMab Fully Human Antibody Programs
for HuMab Fully Human Antibody Programs ' { Vaccine Programs and Associated Vaccine Antigen Targets Utilized MBVX Study study Cancertype MBX St in Tia 10 1 Sarcoma MV.01090001_NcTo1241491 2 Breast 06156 Ncro0870574 3 Melanoma 05.086 cT00s97272 4 OvaranBev 10-099 Ncr01223235 s sac 08.095 Ncro1349687
Slide 13: Pipeline programs
Vi Se Program Discovery _Lead Op Pre-IND Phase 1 Phase 2 ‘HuMab-5B1 for Pancreatic Cancer and CA19-9 malignancies including Lung and Gl Cancers fadoimmuntherapy (MVE3075) ed "erpeut (MVES73): Monotherapy a) ‘Therapeutic (MVT-5873): + Chemo aE ImmunoPET imaging (MVT-2163) aS Ta for Breast and Ovarian
Slide 14: Sialyl Lewis A Target: Phase and Preclinical Program
i, SIALYL LEWIS? TARGET PHASE 1 AND PRECLINICAL PROGRAM Scientific Rationale 1s
Slide 15: Scientific Rationale for Sialyl Lewis A
\\ { Scientific Rationale for Sialyl Lewis? + steis densely expressed in mits of opy + Say Lewis (ste the Hunts target, sens teen pried is exgreredin over 90% of panereate 3nd eriostens —_ ies < a S 4 ‘Pancreat 8. Colonnade, E Sasha oth + HuMab et isintemalzed and ‘ecumates into target cancer cel +
Slide 16: Sialyl Lewis A Target Phase Programs: MVT-5873
i, SIALYL LEWIS? TARGET PHASE 1 PROGRAMS MVT-5873 Therapeutic Antibody Establishes Safety and MTD 16
Slide 17: Single Agent Safety Established in Phase 1a Study
Single Agent Safety Established in Phase 1a Study + Single-agent was generally well tolerated + Dose-limiting toxicities consisting of transient elevations in ALT, AST and bilirubin that typically resolved within a week + Infusion reactions were mitigated with pre-medication and extended infusion ti
Slide 18: Inclusion Criteria Established for Future Clinical Trials
M Inclusion Criteria Established for Future Clinical Trials }2 + Phase 1a identified “responder subset” with at Sem least 50% reduction in CA19-9 levels after single f agent treatment. | = linn Patients at screening that had CA19-9 level < 2500 $ a “um vin a ll Remained on treatment 4 months versus
Slide 19: MVT-2163 PET Imaging Agent Establishes Safety and Targeting Mechanism
i, SIALYL LEWIS? TARGET PHASE 1 PROGRAMS MVT-2163 PET Imaging Agent Establishes Safety and Targeting Mechanism 10
Slide 20: Scientific and Medical Rationale for Imaging and RIT Dosing Strategy
M Scientific and Medical Rationale for Imaging and RIT Dosing Strategy + Existing Immuno-PET and RIT programs with antibody targeting that utilize a Cold- Hot dosing strategy include Betalutin®, ®Zr and *”7Lu J-591, ®°Zr-Trastuzumab_ + Antibodies are processed in the liver and spleen which play a ce
Slide 21: Cold-Hot Dosing Strategy Reduces Liver and Spleen Accumulation
Cold-Hot Dosing Strategy Reduces Liver and Spleen Accumulation Mi Data Support Using the Cold-Hot Dosing Strategy for RIT Program MiP images of two patients illustrating decreased liver SUV after cold pre-dose at day 7 P é Ln OE Concentration ddeaty 10) en 9 0.47 ~«47 ie IL . 7 ecigoumerianmed “ayer
Slide 22: HuMab-5B1 Specifically Targets CA19-9 Positive Tumor Lesions
HuMab-5B1 Specifically Targets CA19-9 Positive Tumor Lesions Focal radiotracer uptake above background was observed in primary tumors and metastases from day 2 and continuously increased through day 7 + Day 7 tumor SUV,,,, Were as high as 101 g/mL FOG PET SUV, values “10 g/mL. + High focal uptake wa
Slide 23: MVT-1075 Radioimmunotherapy (RIT)
i, SIALYL LEWIS? TARGET PHASE 1 PROGRAMS MVT-1075 Radioimmunotherapy (RIT) 23
Slide 24: Radioimmunotherapy (RIT) is Lead Clinical Program
Mi Radioimmunotherapy (RIT) is Lead Clinical Program Antibody-Based Therapeutic Agent to Treat Very Difficult Cancers Such as Pancreatic, Small Cell Lung, Gastric and Colon Established Safety, PK and Responder Subset %, S fe) 3 Therapeutic Antibody (navess73) Established safety, specifiy, ‘accumulat
Slide 25: One Cycle of Treatment
) One Cycle of Treatment Day 1 * MVT-5873 Cold Dose # ~Ahours wait Day 15 * MVT-1075 Hot Dose Day 57 Safety monitoring visits throughout and dosimetry completed day 8 RIT (MVT-1075) Phase 1a Clinical Trial Firstn-Human Phase 1 Fest patint dove une 2017 with no OUT: + Nonrandomized open label, dose-x
Slide 26: RIT (MVT-1075) Phase 1 Trial 2017
+ Firstin-Human dose June 2017 + Two clinical sites will ad enrollment: Honor Health nated) and MSKCC (planned 03) + Enroll ~6 patients in 2017 + Establish MTD middle of 2018 (estimate 12 patients) Y FDAAuthorization to |v First Clinical Site : Proceed Initiated ¥ First in Human Dose RIT (MVT-1075)
Slide 27: Intellectual Property and Milestones
i, INTELLECTUAL PROPERTY AND CORPORATE UPDATE 27
Slide 28: Robust Intellectual Property
Robust Intellectual Property ion Number ‘us9475874 62 1s 2015/056194 At Wo 2015/053871 02 carme7ea, 0 2015/053871 a4 Wo 2015/053871 A8 14244297000 R 20160054501 4 mason cw 1057645268 sp 2016524725 US2017/015756 at 0 2018/083871 43 eP20nso7At Granted Patent Patent Application Patent Applicaton Patent
Slide 29: Milestones and News Flow
Milestones and News Flow Preclin @ AACR noes ater 5 File Orphan | Phase 10 Interim ee Barc Chemo Combination Es PET Imaging Agent HuMab-581 Fe Optimized Phase 1a @ SAM Select Leod Candidate Intdote ND Ending 7 Peptak Podlame inate rows ‘tounet oan ror see eed cant 7a ee | Sete od canoe Tales ore pla
Slide 30: Recent Corporate Events
Recent Corporate Events Mi + Company has engaged Greenhill & Co. to assist company in evaluating strategic options to unlock shareholder value Assist in evaluating transaction options including full company sale, licensing ‘agreements or asset sale coupled with a reverse merger Engaged in discussion
Slide 31: Financial Snapshot
M Financial Snapshot NASDAQ MBvx Share Price* $0.66 Market Cap* $7.0M 3M Avg. Daily Volume* 203K Common Stock Outstanding/Public Float 11.2M Preferred Stock (Common Equivalents) 13.2M Cash as of June 30, 2017 $1.8M Registered Direct, net, September 2017 $1.9M * ut atetsetembe 1.2017
Slide 32: Radioimmunotherapy (MVT-1075) program guided by recent clinical experience
dS + Radioimmunotherapy (MVT-1075) program guided by recent clinical experience 50 patients in three active clinical investigations with the HuMab-5B1 Antibody Data from completion of two Phase 1 studies accelerates RIT program First patient dosed in June Early readout of RIT clinical data by end of
Slide 33: MabVax Therapeutics
MabVa» therapeutics NASDAQ: MBVX ‘wirenabvatlae
MabVax Therapeutics Holdings — Investor Presentation (September 2017) on 6ix